Rebeca Rosas-Campos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rebeca Rosas-Campos has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Juan Armendariz-Borunda
Universidad de Guadalajara
2 shared publications - Adriana Franco-Acevedo
Department of Pathology and Laboratory Medicine, University of California, Los Angeles, CA 90095, USA
1 shared publication Ana Sandoval-Rodriguez
Instituto de Biología Molecular en Medicina y Terapia Génica, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, México
1 shared publication- Elda Cristina Villaseñor-Tapia
EMCS, Tecnologico de Monterrey, Zapopan 45201, Jalisco, Mexico
1 shared publication - Fernando Caloca-Camarena
Programa de Doctorado en Farmacología, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico; Instituto de Biología Molecular en Medicina y Terapia Génica, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico
1 shared publication - Hugo Christian Monroy-Ramirez
Universidad de Guadalajara
1 shared publication
Latest Publications
- 23 May 2026
- Published by Elsevier in Cellular Signalling
- Vol. 145, 112614
N-acetylcysteine–induced transcriptomic reprogramming regulates Nrf2-mediated signaling and redox homeostasis in experimental hepatocellular carcinoma
- 23 May 2026
- Published by Elsevier in Cellular Signalling
- Vol. 145, 112614
N-acetylcysteine–induced transcriptomic reprogramming regulates Nrf2-mediated signaling and redox homeostasis in experimental hepatocellular carcinoma
- Open Access
- 9 May 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (5) , 584
Novel Pharmacological and Nanotechnology-Based Therapeutic Strategies for MASLD
Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly prevalent global health concern driven by metabolic imbalance and excess caloric intake, leading to hepatic steatosis, inflammation, and fibrosis that may progress to metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, or hepatocellular carcinoma. Current management relies primarily on lifestyle interventions and, in advanced stages, pharmacological therapies; however, long-term outcomes remain limited due to variable efficacy and poor sustainability. Recent advances in pharmacotherapy, including GLP-1 receptor agonists, THR-β agonists and SGLT2 inhibitors, have shown clinically meaningful improvements in metabolic parameters and hepatic steatosis, although their impact on fibrosis and long-term disease modification remains uncertain. In parallel, genomic and nanotechnology-based strategies (such as RNA-based therapies and nanoparticle delivery systems) have emerged as promising approaches to enhance drug stability, targeting, and therapeutic precision. Despite these advances, most emerging strategies remain at preclinical or early translational stages, with significant challenges related to safety, scalability, regulatory approval, and long-term efficacy. In this context, this review provides an integrative synthesis of pharmacological, genomic, and nanotechnology-based therapies, highlighting their mechanisms, limitations, and translational potential. Future research should focus on well-designed clinical trials, standardized evaluation frameworks, and the development of personalized therapeutic approaches. The convergence of these strategies may enable more effective and durable interventions for MASLD.
- 9 May 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (5) , 584
Open AccessNovel Pharmacological and Nanotechnology-Based Therapeutic Strategies for MASLD
Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly prevalent global health concern driven by metabolic imbalance and excess caloric intake, leading to hepatic steatosis, inflammation, and fibrosis that may progress to metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, or hepatocellular carcinoma. Current management relies primarily on lifestyle interventions and, in advanced stages, pharmacological therapies; however, long-term outcomes remain limited due to variable efficacy and poor sustainability. Recent advances in pharmacotherapy, including GLP-1 receptor agonists, THR-β agonists and SGLT2 inhibitors, have shown clinically meaningful improvements in metabolic parameters and hepatic steatosis, although their impact on fibrosis and long-term disease modification remains uncertain. In parallel, genomic and nanotechnology-based strategies (such as RNA-based therapies and nanoparticle delivery systems) have emerged as promising approaches to enhance drug stability, targeting, and therapeutic precision. Despite these advances, most emerging strategies remain at preclinical or early translational stages, with significant challenges related to safety, scalability, regulatory approval, and long-term efficacy. In this context, this review provides an integrative synthesis of pharmacological, genomic, and nanotechnology-based therapies, highlighting their mechanisms, limitations, and translational potential. Future research should focus on well-designed clinical trials, standardized evaluation frameworks, and the development of personalized therapeutic approaches. The convergence of these strategies may enable more effective and durable interventions for MASLD.